About Freya Biosciences
Freya Biosciences is a company based in Copenhagen (Denmark) founded in 2023 by Johan E T Van Hylckama Vlieg, Colleen Acosta, and Thomas Gundelund Rasmussen. It operates as a HealthTech. Freya Biosciences has raised $49.8 million across 2 funding rounds from investors including Gates Foundation, Danmarks Eksport og Investeringsfond and Sofinnova Partners. The company has 16 employees as of November 30, 2024. Freya Biosciences offers products and services including FB101, IVF Support Therapy, and Endometriosis Treatment. Freya Biosciences operates in a competitive market with competitors including Aphrodite Health, health mavens and ELAINE studies, among others.
- Headquarter Copenhagen, Denmark
- Employees 16 as on 30 Nov, 2024
- Founders Johan E T Van Hylckama Vlieg, Colleen Acosta, Thomas Gundelund Rasmussen
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
-$11.77 M (USD)-152as on Dec 31, 2023
-
EBITDA
-$12.57 M (USD)-121as on Dec 31, 2023
-
Total Equity Funding
$49.8 M (USD)
in 2 rounds
-
Latest Funding Round
$11.8 M (USD), Series A
Nov 19, 2024
-
Investors
Gates Foundation
& 7 more
-
Employee Count
16
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Freya Biosciences
Freya Biosciences offers a comprehensive portfolio of products and services, including FB101, IVF Support Therapy, and Endometriosis Treatment.
Therapeutic solution targeting vaginal dysbiosis for women.
Therapy addressing dysbiosis for improved IVF outcomes.
Treatment targeting dysbiosis linked to endometriosis infertility.
Funding Insights of Freya Biosciences
Freya Biosciences has successfully raised a total of $49.8M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.8 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Freya Biosciences
Freya Biosciences has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Danmarks Eksport og Investeringsfond and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in transformative biotech companies by OMX Ventures.
|
Locked | Locked | Locked | |
|
Angelini Ventures is focused on investing in BioTech and Digital Health.
|
Locked | Locked | Locked |
Investor details for Freya Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Freya Biosciences
Investment portfolio details for Freya Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Freya Biosciences
Detailed financials for Freya Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Freya Biosciences Comparisons
Peer comparison for Freya Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Freya Biosciences
Freya Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aphrodite Health, health mavens and ELAINE studies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Psychedelic medicines for women are developed by this CRO.
|
|
| Locked | Locked | Locked |
Offers clinical development services as a CRO focused on drugs for women's health.
|
|
| Locked | Locked | Locked |
Conducts research and trials for breast cancer drugs like lasofoxifene.
|
Detailed competitors of Freya Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Freya Biosciences
Complete news archive for Freya Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Freya Biosciences
Freya Biosciences was founded in 2023.
Freya Biosciences is headquartered in Copenhagen, Denmark.
Colleen Acosta is the current CEO of Freya Biosciences. They have also founded this company.
Freya Biosciences is a funded company, having raised a total of $49.8M across 2 funding rounds to date.
As of Nov 30, 2024, the latest employee count at Freya Biosciences is 16.
Freya Biosciences is engaged in creating innovative microbial immunotherapies to address chronic inflammation and immune dysregulation in womens reproductive health. Solutions are developed for conditions such as infertility, endometriosis, and preterm birth. The company is supported by a data-driven platform integrating clinical trial results and extensive microbiome and immune marker data. Research and therapeutic development are targeted at improving outcomes in IVF, natural conception, and other reproductive system disorders. Partnerships, such as with Boston IVF, are established to advance clinical studies in the US.
Freya Biosciences's top competitors include Aphrodite Health, health mavens and ELAINE studies.
Freya Biosciences offers FB101, IVF Support Therapy, and Endometriosis Treatment.
Freya Biosciences has 8 investors. Key investors include Gates Foundation, Danmarks Eksport og Investeringsfond, Sofinnova Partners, OMX Ventures, and Angelini Ventures.